Cadila Healthcare has informed that with reference to news appearing in the media this morning, they wish to clarify that this matter very specifically relates to an Untitled Letter issued by the USFDA to Zydus Discovery DMCC (a 100% subsidiary of Cadila Healthcare) and not a Warning Letter. The letter is related to a product promotion of a drug which is not marketed in USA and currently marketed only in India. We have already taken the necessary actions to respond to this letter. As per the USFDA website, ‘Unlike a warning letter, an Untitled Letter does not include a statement warning that failure to promptly correct a violation may result in an enforcement action’.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: